Ccme Global Limited
BSE: CCME · Biotechnology · sector
₹28.98BSE close 2026-10-26
Key numbers
Market cap₹43 cr
Price₹28.98
52w high / low₹130 / ₹26
P/E58.0xSector median 40.2x
P/B1.1xSector median 1.4x
Book value₹27.2
Dividend yield–Sector median 2.11%
ROE-3.5%Sector median -0.0%
ROCE-2.1%Sector median 3.3%
OPM–Sector median 31.3%
Debt / equity0.00xSector median 0.01x
EV/EBITDA–Sector median 34.1x
Interest cover–
Current ratio8.64x
Sales growth 3y–Sector median -26.4%
Profit growth 3y–Sector median -43.0%
PEG–
Last 12 months to Jun 2026, Standalone. "Sector median" = middle value of 6 companies in Biotechnology (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹37 cr vs borrowings ₹0 cr (FY26): cash is higher (net cash).
- Net loss in 6 of the last 6 quarters.
- No dividend in the last 5 financial years.
- Price ₹28.98 on 2026-10-26: -77.7% from the 52-week high, +9.7% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹184.90 · low ₹15.85
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -0 | -0 | -0 | -0 | -1 | -0 |
| OPM % | – | – | – | – | – | – |
| Other income | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | -0 | -0 | -0 | -0 | -0 | -0 |
| EPS (₹) | 0.02 | 0.09 | 0.05 | 0.02 | 0.37 | 0.06 |
| Revenue YoY | – | – | ||||
| Profit YoY | – | – |
Standalone figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | – | – | – | 0 | 0 | 0 |
| EBITDA | -0 | -0 | -4 | -0 | -1 | -1 |
| Net profit | -0 | -0 | -4 | 4 | -1 | -1 |
| EPS (₹) | -0.09 | -0.11 | -2.92 | 2.70 | 0.53 | 0.50 |
| Revenue growth | – | – | – | – | – | |
| Profit growth | – | – | – | -120.3% | – | |
| Dividend / share (₹) | – | – | – | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | – | – | – |
| Net profit | – | – | – |
| EPS | – | – | – |
| Share price | – | – (2y) | – |
Balance sheet
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Shareholders' equity | 9 | 40 |
| Borrowings | 0 | 0 |
| Cash & equivalents | 0 | 37 |
| Total assets | 9 | 45 |
| Fixed assets | 0 | 0 |
| Capital work in progress | 0 | 0 |
| Investments | 0 | 0 |
| Receivables | 0 | 0 |
| Inventory | 0 | 0 |
| Payables | 0 | 0 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Cash from operations | 0 | 5 |
| Cash from investing | 0 | 0 |
| Cash from financing | 0 | 32 |
| Capex | 0 | 0 |
| Free cash flow | 0 | 5 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY25 | FY26 |
|---|---|---|
| ROE % | 41.1% | -1.8% |
| ROCE % | 41.1% | -1.8% |
Peers in Biotechnology
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| ANTHEM | ₹46,324 cr | 80.2x | 15.2x | 18.9% | 25.5% | 38.4% | – | – |
| ADVENZYMES | ₹2,823 cr | 17.0x | 1.7x | 10.9% | 14.1% | 31.3% | +11.3% | 2.11% |
| CCME | ₹43 cr | 58.0x | 1.1x | -3.5% | -2.1% | – | – | – |
| VIVOBIOT | ₹29 cr | 3.6x | 0.3x | -3.3% | 5.8% | 37.0% | +1.1% | – |
| SHREEGANES | ₹18 cr | 22.5x | 0.3x | -0.6% | -0.6% | -35.1% | -57.0% | – |
| GVBL | ₹12 cr | 329.9x | 3.1x | 0.5% | 0.8% | 15.6% | -53.8% | – |
Documents
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Biotechnology |
| Sub-industry | Biotechnology |
| Symbol | CCME |
| BSE code | 514336 |
| ISIN | INE194N01016 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-24 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = BSE close 2026-10-26.